Endobronchial Ultrasound Biopsy Market Size 2032
Endobronchial Ultrasound Biopsy Market Size and Forecast (2025 - 2032), By Procedure Type (EBUS-TBNA, EBUS-TBLB, EBUS-GS), By Application (Lung Cancer, Lymphoma, Sarcoidosis, Others), By End-user (Hospitals, Specialty Clinics, Ambulatory Surgery Centers), and Geography.
Report Highlights:
From 2025 to 2032 the worldwide Endobronchial Ultrasound Biopsy Market is expected to expand at a CAGR of 4.4%. From USD 678.4 million in 2022 to USD 1,245.6 million by 2032 the market value is predicted to rise. Over the projection period, North America is expected to control the market.
Rising lung cancer and other respiratory illnesses are driving notable increase in the endobronchial ultrasound biopsy market. Key drivers of market growth in EBUS systems include technological developments in them, rising acceptance of minimally invasive diagnostic techniques, and increased consciousness about early illness diagnosis. Furthermore driving market expansion are growing elderly populations and better healthcare facilities in underdeveloped nations.
Market Dynamics:
Market Trend: Move toward same-day discharges and outpatient surgeries for EBUS biopsies.
Thanks to developments in anesthetic methods and technology, outpatient EBUS surgeries are becoming more and more popular. This change is lowering healthcare expenses, raising patient comfort, and streamlining procedures. As outpatient treatments, hospitals and specialized clinics are using EBUS biopsies more and more so that patients may go back home on the same day. Developed nations with established healthcare systems show especially this tendency. Improvements in post-procedure care and patient education also help to justify the shift toward outpatient EBUS by allowing safe and efficient home recovery. The trend toward outpatient EBUS operations is projected to accelerate even more as healthcare providers keep streamlining their processes and resource allocation, hence perhaps increasing access to this diagnostic instrument for a larger patient population.
Market Driver: Rising lung cancer prevalence and increased need for precise staging
The Endobronchial Ultrasound Biopsy Market is mainly driven by the worldwide growing prevalence of lung cancer. With smoking, air pollution, and occupational exposures driving its frequency, lung cancer continues to be among the top cancer-related fatalities globally. Offering a less invasive substitute for more involved surgical operations, EBUS has become more important for accurate detection and staging of lung cancer. Determining the degree of cancer dissemination and guiding treatment options depend on exact sampling of mediastinal and hilar lymph nodes made possible by this approach. The demand for premium tissue samples acquired by EBUS has increased as oncologists depend more and more on genetic profiling and tailored treatment techniques. Furthermore, the method's capacity to identify minor, peripheral lung nodules makes it useful for early-stage lung cancer diagnosis in line with the worldwide drive for earlier cancer identification and better survival rates.
Restraints in the Market High initial equipment expenditures and limited availability of qualified operators
The restricted availability of trained operators and the high starting expenses connected with EBUS technology impede the expansion of the endobronchial ultrasound biopsy market. EBUS operations need specific knowledge of both bronchoscopy and ultrasonic imaging as well as training. Particularly in smaller healthcare institutions and developing areas, the learning curve for EBUS procedures may be high and experienced operators are typically scarce. Longer patient waiting times and maybe restricted access to the operation might result from this shortfall. Furthermore problematic for many healthcare institutions, particularly in resource-limited environments, are the high cost of EBUS systems including the ultrasonic processor, bronchoscopes, and needles. The general cost of ownership is further increased by the requirement of frequent maintenance and updates. These elements taken together might limit the acceptance of EBUS technology, especially in smaller hospitals and clinics, therefore perhaps resulting in differences in access to this useful diagnostic tool across many healthcare environments and geographical areas.
Segment Overview:
With great diagnostics precision and adaptability, EBUS-TBNA rules the industry.
The most often used technique available on the market is endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA.). This method is very helpful for lung cancer staging and diagnosis of other thoracic disorders as it lets one see real-time and sample mediastinal and hilar lymph nodes. High sensitivity and specificity provided byEBUS-TBNA help to lower the need for more intrusive surgical operations by Pulmonologists and thoracic surgeons all over use it because of its capacity to reach challenging locations and provide precise findings.
Regional Outlook:
North America leads the market because of strong adoption rates and excellent healthcare infrastructure.
Driven by factors like the great incidence of lung cancer, well-established healthcare infrastructure, and early acceptance of innovative medical technology, North America leads the Endobronchial Ultrasound Biopsy Market. Particularly the United States explains a considerable market share because of its high patient population and strong reimbursement rules for EBUS operations. Further supporting market expansion is the region's great concentration on cancer research and development of less invasive diagnostic approaches. Furthermore supporting North America's market leadership are important companies in the industry and continuous technical developments in EBUS systems. The region's healthcare professionals' focus on early cancer identification and appropriate staging fits very well with EBUS's capacity, which is why it is so widely used in hospitals and specialized clinics.
Competitive Landscape:
Strong rivalry among important companies trying to develop and increase their market presence defines the Endobronchial Ultrasound Biopsy Market. Leading firms are concentrating on creating sophisticated EBUS systems with better image quality, needle design, and interaction with other diagnostic modalities. Common strategic partnerships aiming at improving product offers and increasing geographical reach are those between research facilities and healthcare providers. Many stakeholders are also funding training initiatives to close the skill gap and advance more general acceptance of EBUS technology. Miniaturization of equipment and the creation of single-use bronchoscopes to handle issues with infection control are trends in the industry. Growing demand for minimally invasive diagnostic techniques is projected to drive more intense competition, which can result in more technical innovations and market consolidation.
Major Players:
- Olympus Corporation
- PENTAX Medical
- FUJIFILM Corporation
- Boston Scientific Corporation
- Medtronic plc
- Cook Medical
- Veran Medical Technologies
- CONMED Corporation
- Medi-Globe GmbH
- Merit Medical Systems, Inc.
Key Developments:
-
Olympus Corporation debuted a new EBUS-TBNA device with enhanced imaging capability and needle design in 2023.
-
Medtronic plc's new single-use EBUS bronchoscope was FDA approved in 2022, therefore addressing issues with infection control in healthcare environments.
1. INTRODUCTION
1.1. Market Definition
1.2. Study Scope
1.3. Currency Conversion
1.4. Study Period (2025- 2032)
1.5. Regional Coverage
2. RESEARCH METHODOLOGY
2.1. Primary Research
2.2. Secondary Research
2.3. Company Share Analysis
2.4. Data Triangulation
3. EXECUTIVE SUMMARY
3.1. Global Endobronchial Ultrasound Biopsy Market (2025 – 2032)
3.2. Global Endobronchial Ultrasound Biopsy Market (2025 – 2032)
3.2.1. Market Segment By Procedure Type (2025 – 2032)
3.2.2. Market Segment By Application (2025 – 2032)
3.2.3. Market Segment By End-user (2025 – 2032)
4. MARKET DYNAMICS
4.1. Market Trends
4.1.1. Shift towards outpatient procedures and same-day discharges for EBUS biopsies
4.1.2. Integration of artificial intelligence in EBUS image interpretation
4.1.3. Development of hybrid bronchoscopy-EBUS systems
4.2. Market Drivers
4.2.1. Increasing incidence of lung cancer and growing demand for accurate staging
4.2.2. Technological advancements in EBUS systems improving diagnostic accuracy
4.2.3. Rising preference for minimally invasive diagnostic procedures
4.3. Market Restraints
4.3.1. Limited availability of skilled operators and high initial equipment costs
4.3.2. Reimbursement challenges in some regions
4.4. Porter's Five Forces Analysis
4.4.1. Threat of New Entrants
4.4.2. Bargaining Power of Buyers/Consumers
4.4.3. Bargaining Power of Suppliers
4.4.4. Threat of Substitute Products
4.4.5. Intensity of Competitive Rivalry
4.5. Supply Chain Analysis
4.6. Pricing Analysis
4.7. Regulatory Analysis
4.8. Pipeline Analysis
5. BY PROCEDURE TYPE (MARKET VALUE (US$ MILLION) – 2025-2032*)
5.1. EBUS-TBNA
5.2. EBUS-TBLB
5.3. EBUS-GS
6. BY APPLICATION
6.1. Lung Cancer
6.2. Lymphoma
6.3. Sarcoidosis
6.4. Others
7. BY END-USER
7.1. Hospitals
7.2. Specialty Clinics
7.3. Ambulatory Surgery Centers
8. GEOGRAPHY
8.1. North America
8.1.1. United States
8.1.2. Canada
8.1.3. Mexico
8.2. South America
8.2.1. Brazil
8.2.2. Argentina
8.2.3. Rest of South America
8.3. Europe
8.3.1. Germany
8.3.2. United Kingdom
8.3.3. France
8.3.4. Italy
8.3.5. Spain
8.3.6. Russia
8.3.7. Rest of Europe
8.4. Asia-Pacific
8.4.1. China
8.4.2. Japan
8.4.3. India
8.4.4. Australia
8.4.5. South Korea
8.4.6. Rest of Asia-Pacific
8.5. Middle-East
8.5.1. UAE
8.5.2. Saudi Arabia
8.5.3. Turkey
8.5.4. Rest of Middle East
8.6. Africa
8.6.1. South Africa
8.6.2. Egypt
8.6.3. Rest of Africa
9. COMPETITIVE LANDSCAPE
9.1. Key Developments
9.2. Company Market Share Analysis
9.3. Product Benchmarking
10. SWOT ANALYSIS
11. COMPANY PROFILES
11.1. Olympus Corporation
11.2. PENTAX Medical
11.3. FUJIFILM Corporation
11.4. Boston Scientific Corporation
11.5. Medtronic plc
11.6. Cook Medical
11.7. Veran Medical Technologies
11.8. CONMED Corporation
11.9. Medi-Globe GmbH
11.10. Merit Medical Systems, Inc.
11.11. Veracyte, Inc.
11.12. Biodesix, Inc. (*LIST NOT EXHAUSTIVE)
12. MARKET OPPORTUNITIES
By Procedure Type:
- EBUS-TBNA
- EBUS-TBLB
- EBUS-GS
By Application:
- Lung Cancer
- Lymphoma
- Sarcoidosis
- Others
By End-user:
- Hospitals
- Specialty Clinics
- Ambulatory Surgery Centers
By Region:
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Frequently Asked Questions
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511